ASA: No Drop in Recurrent Stroke Seen With Apixaban After Cryptogenic Stroke
By Elana Gotkine HealthDay Reporter
FRIDAY, Feb. 16, 2024 -- For patients with recent cryptogenic stroke and evidence of atrial cardiopathy, the risk for recurrent stroke is not reduced with apixaban versus aspirin, according to a study published online Feb. 7 in the Journal of the American Medical Association to coincide with the annual American Stroke Association International Stroke Conference, held from Feb. 7 to 9 in Phoenix.
Hooman Kamel, M.D., from Weill Cornell Medicine in New York City, and colleagues compared anticoagulation to antiplatelet therapy for secondary stroke prevention in a multicenter trial involving 1,015 participants with cryptogenic stroke and evidence of atrial cardiopathy. At the time of randomization, participants had no evidence of atrial fibrillation. Participants were randomly allocated to receive apixaban (5 mg or 2.5 mg) twice daily or aspirin (81 mg) once daily (507 and 508 patients, respectively).
After a planned interim analysis, the trial was stopped for futility after enrollment of 1,015 of the target 1,100 participants and at a mean follow-up of 1.8 years. The researchers found that recurrent stroke occurred in 40 patients in both groups (annualized rate, 4.4 percent in both groups). Symptomatic intracranial hemorrhage occurred in zero and seven patients taking apixaban and aspirin, respectively (annualized rate, 1.1 percent for patients taking aspirin); other major hemorrhages occurred in five patients in both groups (annualized rates, 0.7 and 0.8 percent for those taking apixaban and aspirin, respectively).
"Oral anticoagulant therapy with apixaban did not significantly reduce the risk of recurrent stroke compared with aspirin," the authors write.
The BMS-Pfizer Alliance provided the in-kind study drug, and Roche Diagnostics provided ancillary funding for laboratory supplies.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Risk for Most Cardiovascular Diseases No Higher With Inflammatory Bowel Disease
FRIDAY, May 3, 2024 -- Among postmenopausal women with inflammatory bowel disease (IBD), there is no higher risk for cardiovascular disease (CVD) compared with women without IBD...
Many Stroke Survivors Experience Poststroke Depression
TUESDAY, April 16, 2024 -- Nearly six in 10 stroke survivors experience depression up to 18 years after stroke, according to a study published online March 25 in The Lancet...
Silent Brain Infarct, Cerebral Small Vessel Disease Prevalent in Heart Disease
MONDAY, April 15, 2024 -- The prevalence of silent brain infarction (SBI) and cerebral small vessel disease (CSVD) is high among individuals with heart disease and is similar with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.